Skip to main content

SIACI of cetuximab and bevacizumab

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

  • RegistryNCT05956821
  • PhasePhase 1/2
  • StatusRecruiting
  • ConditionRelapsed/Refractory Intracranial Glioma
  • SponsorUniversity of Miami
How SIACI of cetuximab and bevacizumab worksNCT059568211 min

What the film says

Read the transcript

This trial is for children and young adults under 22 with relapsed or refractory glioma, including glioblastoma and diffuse intrinsic pontine glioma.

The idea: deliver two drugs straight into the arteries that feed the brain. Cetuximab and bevacizumab are infused into an artery, a method called super selective intra-arterial infusion, once a month for up to about a year.

This phase 1 and 2 study looks at safety and response, and plans 20 participants. At the University of Miami, Heather McCrea leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT05956821

    Under 22 with relapsed or refractory glioma, incl. glioblastoma and DIPG; Cetuximab and bevacizumab infused into an artery, super selective, monthly for about a year; Phase 1 and 2; safety and response; 20 participants; University of Miami; Heather McCrea

The drug

What is being tested.

Subjects will receive monthly dosing of bevacizumab (15 mg/kg) and cetuximab (200mg/m2)

The study

How the trial runs.

This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients < 22 years of age.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Documented histologic diagnosis of relapsed or refractory glioblastoma multiforme (GBM), anaplastic astrocytoma (AA), fibrillary astrocytomas (FA), pilomyxoid astrocytoma (PXA), oligodendroglioma, or anaplastic mixed oligoastrocytoma (AOA), or radiologically diagnosed diffuse intrinsic brainstem glioma (DIPG)
  • Must have at least one confirmed and evaluable tumor site
  • Must have a Karnofsky or Lansky performance status ≥60%.
  • No chemotherapy for three weeks prior to treatment
  • Patients must have adequate hematologic reserve with absolute neutrophils≥1000/mm3 and platelets ≥100,000/ mm3
  • Pre-enrollment chemistry parameters must show: bilirubin<1.5x the institutional upper limit of normal (IUNL); Aspartate Aminotransferase( AST) or Alanine transaminase (ALT)<2.5x IUNL and creatinine<1.5x IUNL

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.